Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.
Jed A. Katzel, MD, medical oncologist at Kaiser Permanente Santa Clara, discusses the findings from a study using a generalized competing event model to look at patients with head and neck cancer.
Roy S. Herbst, MD, PhD, Yale Cancer Center, discusses the use of combination immunotherapy for the treatment of lung cancer.
Therapeutic Approach for Stage 4 Gastric Cancer
Susan M. O'Brien, MD, associate director for clinical sciences at UC Irvine Health, shares her insights on why CAR T cells are not as successful in chronic lymphocytic leukemia as compared to lymphoma or acute lymphocytic leukemia. She also discusses what she believes must change in order for this therapy to move up in the treatment landscape for CLL.
Maurie Markman, MD, President of Medicine and Science at the Cancer Treatment Centers of America, discusses where he sees the field of ovarian cancer and other gynecologic cancers headed in the future, based on the research shared at the 2018 ASCO Annual Meeting.
Treatments for Relapsed and Refractory Multiple Myeloma
Laurence J. Heifetz, MD, FACP, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses a novel approach to managing disparities in lung cancer care.
Ignacio I. Wistuba, MD, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, discusses how clinicians can best integrate molecular pathology into their treatment selection for patients with non-small cell lung cancer.
